Insight

Why Your Gut Might Matter in Lung Cancer Treatment – Lung Cancer Europe

Lung Cancer Europe/X

Aug 6, 2025, 03:57

Why Your Gut Might Matter in Lung Cancer Treatment – Lung Cancer Europe

Lung Cancer Europe shared a post on X:

“Gut microbiome has been a health buzzword for a while. But in lung cancer, it’s only just becoming clear it could play a role in treatment.

This Phase 3 study found two gut bacteria linked to both better survival and fewer serious side effects from chemo-immunotherapy.”

Lung Cancer Europe

Title: Gut Microbiota in Advanced NSCLC Receiving Chemoimmunotherapy: An Ancillary Biomarker Study From the Phase III Trial JCOG2007 (NIPPON)

Journal: JTO

Authors: Taiki Hakozaki, Kentaro Tanaka, Yoshimasa Shiraishi, Yuta Sekino, Noriko Mitome, Yusuke Okuma, Tomoiki Aiba, Takahiro Utsumi, Junko Tanizaki, Koichi Azuma, Satoshi Hara, Ryo Morita, Seiji Niho, Toshihide Yokoyama, Ryo Toyozawa, Hidehito Horinouchi, Isamu Okamoto, Yukio Hosomi, Yuichiro Ohe

Read the full article.

Lung Cancer Europe

More posts featuring Lung Cancer Europe on OncoDaily.

cancer gut microbiome gut microbiota Hidehito Horinouchi Isamu Okamoto Junko Tanizaki Kentaro Tanaka Koichi Azuma Lung cancer Lung Cancer Europe Noriko Mitome OncoDaily Oncology Ryo Morita Ryo Toyozawa Satoshi Hara Seiji Niho Taiki Hakozaki Takahiro Utsumi Tomoiki Aiba Toshihide Yokoyama Yoshimasa Shiraishi Yuichiro Ohe Yukio Hosomi Yusuke Okuma Yuta Sekino

Neil Ranasinghe: What’s the Difference Between a Clinician and a Technical Author?

LOCKTAC Molecular Glues Are Changing the Rules of Drug Discovery - Amgen

Top 10 Immunotherapy Trials in Lung Cancer to Watch at ESMO 2025

FDA has Granted Full Market Approval for Papzimeos - NIH

Kirsty Duncan։ Thirty-two Months Into Fighting Cancer...